Insider · CIK 0002020969
Najat Khan
Files at RXRX (RECURSION PHARMACEUTICALS, INC.). First filing Aug 19, 2025, latest Sep 10, 2026.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RXRX: RECURSION PHARMACEUTICALS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 22Weak | RECURSION PHARMACEUTICALS, INC. | $79k 22,408 shares | -1% | - | |
| 35Weak | RECURSION PHARMACEUTICALS, INC. | $202k 36,599 shares | -5% | +39% from low-49% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -22,408 | $3.52 | $79k | 2,072,890 | 32 d ago |
| Aug 15, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | FTax withholding Class A Common Stock | -3,789 | $5.64 | $21k | 704,796 | Aug 19, 2025 |
| Aug 18, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock | -36,599 | $5.52 | $202k | 668,197 | Aug 19, 2025 |
| May 15, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | FTax withholding Class A Common Stock | -3,796 | $4.25 | $16k | 708,585 | May 19, 2025 |
| Feb 3, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +210,113 | $0.00 | $0 | 707,085 | Feb 5, 2025 |
| Feb 3, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +8,049 | $0.00 | $0 | 715,134 | Feb 5, 2025 |
| Feb 3, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | FTax withholding Class A Common Stock | -2,753 | $7.25 | $20k | 712,381 | Feb 5, 2025 |
| Feb 3, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +420,226 | $0.00 | $0 | 420,226 | Feb 5, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.